Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial
Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006397?dgcid=rss_sd_all
Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006397?dgcid=rss_sd_all
“Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial.” Clinical Microbiology and Infection.
@article{article40990,
title = {Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006397?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...